Trials / Unknown
UnknownNCT03792568
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Changzheng Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | ALK Inhibitor | Any ALK inhibitor like crizotinib, alectinib and so on. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2019-03-01
- Completion
- 2021-03-01
- First posted
- 2019-01-03
- Last updated
- 2019-02-15
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03792568. Inclusion in this directory is not an endorsement.